Stocks · News reference
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12
Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $9 to $12.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 20, 2026, 3:35 PM
- Checked
- Aug 20, 2026, 3:35 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
UPDATE: Xeris Biopharma Holdings Q2 Adj. EPS $0.00, Inline
Read original at benzinga8-K filing — Xeris Biopharma Holdings, Inc. (XERS)
Filed: 2026-08-06 AccNo: 0001867096-26-000063 Size: 334 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar